.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDis.A02BC02_Pantoprazole.Pantoprazole_1 .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDis.A02BC02_Pantoprazole.Pantoprazole_1| name: | Pantoprazole_1 |
| ATC code: | A02BC02_1 | route: | oral |
| n-compartments | 2 |
Pantoprazole is a proton pump inhibitor (PPI) used for the treatment of gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and other acid-related disorders. It works by inhibiting the gastric H+/K+-ATPase enzyme, thereby reducing gastric acid secretion. It is approved for use in many countries and is available both as oral and intravenous formulations.
Pharmacokinetic parameters reported for healthy adult volunteers following single oral dose of pantoprazole.
Gawrońska-Szklarz, B, et al., & Drozdzik, M (2012). CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. European journal of clinical pharmacology 68(9) 1267–1274. DOI:10.1007/s00228-012-1252-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22418828
Kearns, GL, et al., & Paul, J (2008). Single-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescents. Journal of clinical pharmacology 48(11) 1356–1365. DOI:10.1177/0091270008321811 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18664620
McCann, S, et al., & Gonzalez, D (2023). Population Pharmacokinetics of Posaconazole in Immune-Compromised Children and Assessment of Target Attainment in Invasive Fungal Disease. Clinical pharmacokinetics 62(7) 997–1009. DOI:10.1007/s40262-023-01254-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37179512